{"id":"W4387060869","doi":"10.1007/s13555-023-01017-8","title":"Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","year":2023,"lang":"en","type":"letter","venue":"Dermatology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Discontinuation; Ixekizumab; Medicine; Adalimumab; Psoriasis; Dermatology; Dosing; Internal medicine; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01253442,0.0005878723,0.001567831,0.0005745894,0.0006872155,0.00031213,0.001544977,0.0008507476,0.0002697499],"category_scores_gemma":[0.001009654,0.0003347808,0.0001731795,0.0005548265,0.0002504217,0.0001908765,0.00009184939,0.001654109,0.003102532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002213755,"about_ca_system_score_gemma":0.0002568291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006745758,"about_ca_topic_score_gemma":0.004442027,"domain_scores_codex":[0.9914442,0.003730671,0.002573505,0.001014653,0.000262255,0.0009746694],"domain_scores_gemma":[0.9882771,0.00871095,0.001157985,0.001659905,0.00007843044,0.0001156706],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001325223,0.00003230141,0.008523431,0.00007713747,0.0002629916,0.0001636677,0.006480682,0.00003862559,1.772748e-7,0.0003524054,0.9824706,0.000272724],"study_design_scores_gemma":[0.002415975,0.0002264874,0.03707378,0.00008833502,0.00001902355,0.0002765332,0.0003006799,0.00005478056,0.00000113832,0.0003021153,0.9587704,0.0004707595],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.08835223,0.00133311,0.0004290452,0.9023543,0.003975372,0.002928148,0.0004813208,0.00005395115,0.00009249997],"genre_scores_gemma":[0.06744155,0.0003986947,0.00004193944,0.9174654,0.01153285,0.00179644,0.00006351862,0.0001096212,0.001149961],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02855035,"threshold_uncertainty_score":0.9999104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.157956019820155,"score_gpt":0.3788201942551079,"score_spread":0.2208641744349528,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}